Scientists are applying decades of HIV research experience to the development of SARS-CoV-2 vaccines in the race to end the pandemic.

SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?

Linda-Gail Bekker talks about how she came to work on HIV and shares her thoughts on an evolving field.

Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.

Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.

More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.

We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.

Remembering Bonnie Mathieson: A champion of young scientists

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.